Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 284

Sort by

Sort Order Select

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood . 2020;136(2):157-170.

Blood (2021) 137 (21): 3003.

https://doi.org/10.1182/blood.2021012067

Published: 2021

Journal Articles

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms

Justin Taylor, Xiaoli Mi, Khrystyna North, Moritz Binder, Alexander Penson, Terra Lasho, Katherine Knorr, Michael Haddadin, Bo Liu, Joseph Pangallo, Salima Benbarche, Daniel Wiseman, Ayalew Tefferi, Stephanie Halene, Yang Liang, Mrinal M. Patnaik, Robert K. Bradley, Omar Abdel-Wahab

Blood (2020) 136 (13): 1477–1486.

https://doi.org/10.1182/blood.2020006868

Published: 2020

Includes: Supplemental data

Journal Articles

SF3B1 : the lord of the rings in MDS

Laura Palomo, Francesc Solé

Blood (2020) 136 (2): 149–151.

https://doi.org/10.1182/blood.2020005719

Published: 2020

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

https://doi.org/10.1182/blood.2020004850

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

Joseph Pangallo, Jean-Jacques Kiladjian, Bruno Cassinat, Aline Renneville, Justin Taylor, Jacob T. Polaski, Khrystyna North, Omar Abdel-Wahab, Robert K. Bradley

Blood (2020) 135 (13): 1032–1043.

https://doi.org/10.1182/blood.2019002894

Published: 2020

Includes: Supplemental data

Journal Articles

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Blood (2019) 134 (21): 1821–1831.

https://doi.org/10.1182/blood.2019001187

Published: 2019

Includes: Supplemental data

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Blood (2019) 134 (Supplement_1): 516.

https://doi.org/10.1182/blood-2019-129520

Published: 2019

Journal Articles

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

Daichi Inoue, MD PhD, Chew Guo-Liang, Bo Liu, PhD, Stanley C Lee, PhD, Brittany C Michel, Joey Pangallo, B.S., Andrew R D'Avino, Khrystyna North, Lillian E Bitner, BSc, Muran Xiao, Susumu Kobayashi, Akihide Yoshimi, MD PhD, Hana Cho, MSc, Sydney X Lu, MD PhD, Justin Taylor, MD, Cigall Kadoch, PhD, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2019) 134 (Supplement_1): 637.

https://doi.org/10.1182/blood-2019-124616

Published: 2019

Journal Articles

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Thorsten Zenz, MD, Almut Luetge, Junyan Lu, PhD, Huellein Jennifer, PhD, Sascha Dietrich, MD, Leopold Sellner, MD, Wolfgang Huber, PhD

Blood (2019) 134 (Supplement_1): 1742.

https://doi.org/10.1182/blood-2019-126388

Published: 2019

Journal Articles

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Yasunobu Nagata, MD PhD, Ran Zhao, Hassan Awada, Cassandra M Kerr, MS, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Jacob Scott, MD, Mikkael A. Sekeres, MD MS, Brian P. Hobbs, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1716.

https://doi.org/10.1182/blood-2019-127285

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

Journal Articles

Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS

Manja Meggendorfer, PhD, Wencke Walter, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 4663.

https://doi.org/10.1182/blood-2019-126449

Published: 2019

Journal Articles

Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation

Mathieu Meunier, Camille Knosp, Chloe Friedrich, Johanna Zannoni, Jean-Yves Cahn, MD PhD, Olivier Kosmider, PharmD, PhD, Michaela Fontenay, MD PhD, Sophie Park, MD PhD

Blood (2019) 134 (Supplement_1): 1705.

https://doi.org/10.1182/blood-2019-128407

Published: 2019

Journal Articles

Probing Aberrant Splicing in a Novel Model of SF3B1-Mutant Myelodysplastic Syndromes

Courtnee Clough, Stephanie Busch, B.S., Joey Pangallo, B.S., Robert K. Bradley, PhD, Sergei Doulatov, PhD

Blood (2019) 134 (Supplement_1): 1706.

https://doi.org/10.1182/blood-2019-129176

Published: 2019

Journal Articles

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Ali Sakhdari, MD MSc, Caleb Class, PhD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Joseph D. Khoury, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, L. Jeffrey Medeiros, MD, Rashmi Kanagal-Shamanna, MD

Blood (2019) 134 (Supplement_1): 3016.

https://doi.org/10.1182/blood-2019-131774

Published: 2019

Journal Articles

Identification of an Expanded Immature Cell Population in Human Bone Marrow during Erythroid Responses to ESA Treatment

Isabel Juliana F Hofman, PhD, Teresa Mortera-Blanco, PhD, Sigita Venckute Larsson, Sten Eirik Waelgaard Jacobsen, MD PhD, Petter S Woll, PhD, Marios Dimitriou, PhD, Eva Hellstrom Lindberg, MD PhD

Blood (2019) 134 (Supplement_1): 2993.

https://doi.org/10.1182/blood-2019-130065

Published: 2019

Journal Articles

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Daniel Helbig, MD, Ghaith Abu Zeinah, MD, Erica B Bhavsar, BS, Richard R. Furman, MD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 3025.

https://doi.org/10.1182/blood-2019-125426

Published: 2019

NARROW

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood . 2020;136(2):157-170.

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms

SF3B1 : the lord of the rings in MDS

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS

Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation

Probing Aberrant Splicing in a Novel Model of SF3B1-Mutant Myelodysplastic Syndromes

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Identification of an Expanded Immature Cell Population in Human Bone Marrow during Erythroid Responses to ESA Treatment

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only